GC Biopharma Q2 Profit Plunges 94% as Capital Spending Looms
GC Biopharma, whose operating profit fell 61.9% year-on-year in the first half, is reinvesting liquidity secured from the sale of its stake in Curevo into future growth drivers such as an expansion of its Ochang plant. A view of GC Biopharma's …